संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (formaldehyde inactivated) (unii: wd5e5vym2e) (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:erb9sj9vmq), influenza a virus a/darwin/9/2021 san-010 (h3n2) antigen (formaldehyde inactivated) (unii: kja387fhb2) (influenza a virus a/darwin/9/2021 san-010 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:6s4y8a8uey), influenza b virus b/phuket/3073/2013 antigen (formaldehy - influenza a virus a/michigan/45/2015 x-275 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - fluzone® quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluzone quadrivalent is approved for use in persons 6 months of age and older. do not administer fluzone quadrivalent to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11) ], including egg protein, or to a previous dose of any influenza vaccine. pregnancy exposure registry sanofi pasteur inc. is maintaining a prospective pregnancy exposure registry to collect data on pregnancy outcomes following vaccination with fluzone quadrivalent during pregnancy. healthcare providers are encouraged to enroll women who receive fluzone quadrivalent during pregnancy in sanofi pasteur inc.'s vaccination pregnancy registry by calling 1-800-822-2463. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general popul

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 7.5 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen (unii: 69h0yj871t) (influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen - unii:69h0yj871t), influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen (unii: 2i1eol437m) (influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen - unii:2i1eol437m), influenza b virus b/brisbane/60/2008 recombinant hemagglutinin antigen (unii: 058u2312cr) (influenza b virus b/bri - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza a virus subtypes and influenza type b virus contained in the vaccine. flublok is approved for use in persons 18 years of age and older. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see postmarketing experience [6.2] and description [11] ). pregnancy outcomes in women who have been exposed to flublok during pregnancy are being monitored. contact: protein sciences corporation by calling 1-888-855-7871. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. available data on flublok administered to pregnant women are insufficient to inform vaccine-associated risks in pregnant women. a developmental study of flublok has been performed in

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

deseret biologicals, inc. - influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) (unii: mhg4xw7big) (influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:mhg4xw7big), influenza a virus a/hong kong/4801/2014 x-263b (h3n2) hemagglutinin antigen (propiolactone inactivated) (unii: c2c4da5k06) (influenza a virus a/hong kong/4801/2014 x-263b (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:c2c4da5k06), influenza b virus b/ - influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

deseret biologicals, inc. - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) (unii: kfl1w6w9jb) (influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:kfl1w6w9jb), influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated) (unii: 80t3qs071u) (influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

seqirus pty ltd - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) antigen (propiolactone inactivated) (unii: 9jwn7vdq7n) (influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:u6c4gj6wzg), influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated) (unii: a5wli8wk8a) (influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:37h6eg2naq), influenza b vi - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 5 years of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated backg

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

seqirus pty ltd - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) antigen (propiolactone inactivated) (unii: 9jwn7vdq7n) (influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:u6c4gj6wzg), influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated) (unii: a5wli8wk8a) (influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:37h6eg2naq), influenza b vi - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - afluria® is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and type b present in the vaccine. afluria is approved for use in persons 5 years of age and older. afluria is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy category b: a reproductive and developmental toxicity study has been performed in female rats at a dose approximately 265 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to afluria. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, afluria should be given to a pregnant woman only if clearly needed. in the reproductive and developmental toxicity study, the effect